Improving the science of drug development and regulation is important in fulfilling the public health mission of the US Food and Drug Administration (FDA). A decade on from the launch of the Critical Path Initiative, the FDA's Center for Drug Evaluation and Research (CDER) is now participating in more than 20 science-driven consortia to achieve this goal.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Papadaki, M. & Hirsch, G. Curing consortium fatigue. Sci. Transl. Med. 5, 200fs35 (2013).
Acknowledgements
J.W. would like to thank A. Rowzee and H. Smith for their contributions to this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Related links
Related links
FURTHER INFORMATION
Accelerating Medicines Partnership
Advancing Regulatory Science for Public Health — A Framework for FDA's Regulatory Science Initiative
Advancing Regulatory Science at FDA — A Strategic Plan. 2011
Biomarker Qualification Program
Drug Development Tools (DDT) Qualification Programs
Enhancing Benefit–Risk Assessment in Regulatory Decision-Making
Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products
PCORnet: The National Patient-Centered Clinical Research Network
Rights and permissions
About this article
Cite this article
Woodcock, J. Paving the critical path of drug development: the CDER perspective. Nat Rev Drug Discov 13, 783–784 (2014). https://doi.org/10.1038/nrd4435
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4435